SDStephen M. Day

Stephen M. Day

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen M. Day has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adolescent intermittent ethanol exacerbates amyloid-β with age in the dorsal hippocampus of female TgF344-AD rats

    by Stephen M. Day, Nicole L. Reitz, Lisa M. Savage

    Background: Alcohol misuse increases Alzheimer's disease (ΑD) risk; however, the mechanisms linking these conditions are unknown. In rodents, chronic and acute ethanol increases amyloid-β (Aβ); however, most of those studies have been limited to a single sex or brain region. Objective: This study explored how adolescent intermittent ethanol (AIE), alters Aβ in multiple regions of the brain in female and male TgF344-AD rats as they age. Methods: From postnatal days 28–58, female and male TgF344-AD rats were administered either water (CON) or 5.0 g/kg ethanol (AIE; 20% ethanol w/v) via intragastric gavage on a 2-day on/off cycle. In Experiment 1, Aβ was measured in the medial prefrontal cortex, orbitofrontal cortex (OFC), piriform cortex (PC), entorhinal cortex (EC), ventral hippocampus (vHPC), and dorsal hippocampus (dHPC) in 6- and 10-month-old rats. In Experiment 2, in vivo microdialysis was used in 3-month-old female rats to measure how ethanol directly modulates Aβ levels in the dHPC. Results: In the OFC, PC, EC, vHPC, and dHPC, Aβ 40 and Aβ 42 was higher in 6-month-old female TgF344-AD rats compared to males. However, at 10 months Aβ 40 and Aβ 42 levels were only elevated in the dHPC of AIE-treated females, compared to all other groups. An acute ethanol challenge at 3 months selectively evoked a sustained increase in interstitial fluid Aβ 40 levels in AIE-treated females. Conclusions: In aged females, the dHPC is a region sensitive to ethanol-associated Aβ pathology. This may be due to disruptions in Aβ clearance in early life, which may have an additive effect on Aβ aggregation over the lifespan.

  • Open Access

    Adolescent intermittent ethanol exacerbates Aβ with age in the dorsal hippocampus of female TgF344-AD rats

    by Stephen M. Day, Nicole L. Reitz, Lisa M. Savage

    Background: Alcohol misuse increases Alzheimer’s disease (ΑD) risk, however the mechanisms linking these conditions are unknown. In rodents, chronic and acute ethanol increases amyloid-β (Aβ), however those studies have been limited to a single sex or brain region. Objective: This study explored how adolescent intermittent ethanol (AIE), alters Aβ in multiple regions of the brain in female and male TgF344-AD rats as they age. Methods: From P28-P58, female and male TgF344-AD rats were administered either water (CON) or 5.0 g/kg ethanol (AIE; 20% ethanol w/v) via intragastric gavage on a 2-day on/off cycle. In Experiment 1, Aβ was measured in the medial prefrontal cortex (mPFC), orbitofrontal cortex (OFC), piriform cortex (PC), entorhinal cortex (EC), ventral hippocampus (vHPC), and dorsal hippocampus (dHPC) in 6- and 10-month-old rats. In Experiment 2, in vivo microdialysis was used in 3-month-old female rats to measure how ethanol directly modulates Aβ levels in the dHPC. Results: In the OFC, PC, EC, vHPC, and dHPC, Aβ40 and Aβ42 was higher in 6-month-old female TgF344-AD rats compared to males. However, at 10 months Aβ40 and Aβ42 levels were only elevated in the dHPC of AIE-treated females, compared to all other groups. An acute ethanol challenge at 3 months selectively evoked a sustained increase in ISF Aβ40 levels in AIE-treated females. Conclusions: In aged females, the dHPC is a region sensitive to ethanol-associated Aβ pathology. This may be due to disruptions in Aβ clearance in early life, which may have an additive effect on Aβ aggregation over the lifespan.

  • Open Access

    Mediterranean diet, stress resilience, and aging in nonhuman primates

    by Carol A. Shively, Susan E. Appt, Haiying Chen, Stephen M. Day, Brett M. Frye, Hossam A. Shaltout, Marnie G. Silverstein-Metzler, Noah Snyder-Mackler, Beth Uberseder, Mara Z. Vitolins, et al.


  • Open Access

    Mediterranean Diet, Stress Resilience, and Aging in Nonhuman Primates

    by Carol A. Shively, Susan E. Appt, Haiying Chen, Stephen M. Day, Brett M. Frye, Hossam A. Shaltout, Marnie G. Silverstein-Metzler, Noah Snyder-Mackler, Beth Uberseder, Mara Z. Vitolins, et al.

    Persistent psychological stress increases the risk of many chronic diseases of aging. Little progress has been made to effectively reduce stress responses or mitigate stress effects suggesting a need for better understanding of factors that influence stress responses. Limited evidence suggests that diet may be a factor in modifying the effects of stress. However, long-term studies of diet effects on stress reactive systems are not available, and controlled randomized clinical trials are difficult and costly. Here we report the outcomes of a controlled, randomized preclinical trial of the effects of long-term consumption (31 months, ∼ equivalent to 9 human years) of Western versus Mediterranean - like diets on behavioral and physiological responses to acute (brief social separation) and chronic (social subordination) psychosocial stress in 38 adult, socially-housed, female cynomolgus macaques. Compared to animals fed a Western diet, those fed the Mediterranean diet exhibited enhanced stress resilience as indicated by lower sympathetic activity, brisker and more overt heart rate responses to acute stress, more rapid recovery, and lower cortisol responses to acute psychological stress and adrenocorticotropin (ACTH) challenge. Furthermore, age-related increases in sympathetic activity and cortisol responses to stress were delayed by the Mediterranean diet. Population level diet modification in humans has been shown to be feasible. Our findings suggest that population-wide adoption of a Mediterranean-like diet pattern may provide a cost-effective intervention on psychological stress and promote healthy aging with the potential for widespread efficacy. Highlights: There is no population level treatment to reduce stress and associated disease. Mediterranean diet reduced sympathetic activity. Mediterranean diet reduced cortisol response to acute stress and to ACTH challenge. Mediterranean diet delayed age-related increases in sympathetic activity and cortisol responses to stress. These results suggest a dietary strategy to increase stress resilience.


  • Open Access

    Type-2-Diabetes Alters CSF but Not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys

    by Kylie Kavanagh, Stephen M. Day, Morgan C. Pait, William R. Mortiz, Christopher B. Newgard, Olga Ilkayeva, Donald A. Mcclain, Shannon L. Macauley

    Epidemiological studies suggest that individuals with type 2 diabetes (T2D) have a twofold to fourfold increased risk for developing Alzheimer’s disease (AD), however, the exact mechanisms linking the two diseases are unknown. In both conditions, the majority of pathophysiological changes, including glucose and insulin dysregulation, insulin resistance, and AD-related changes in Aβ and tau, occur decades before the onset of clinical symptoms and diagnosis. In this study, we investigated the relationship between metabolic biomarkers associated with T2D and amyloid pathology including Aβ levels, from cerebrospinal fluid (CSF) and fasting plasma of healthy, pre-diabetic (PreD), and T2D vervet monkeys (Chlorocebus aethiops sabaeus). Consistent with the human disease, T2D monkeys have increased plasma and CSF glucose levels as they transition from normoglycemia to PreD and diabetic states. Although plasma levels of acylcarnitines and amino acids remained largely unchanged, peripheral hyperglycemia correlated with decreased CSF acylcarnitines and CSF amino acids, including branched chain amino acid (BCAA) concentrations, suggesting profound changes in cerebral metabolism coincident with systemic glucose dysregulation. Moreover, CSF Aβ40 and CSF Aβ42 levels decreased in T2D monkeys, a phenomenon observed in the human course of AD which coincides with increased amyloid deposition within the brain. In agreement with previous studies in mice, CSF Aβ40 and CSF Aβ42 were highly correlated with CSF glucose levels, suggesting that glucose levels in the brain are associated with changes in Aβ metabolism. Interestingly, CSF Aβ40 and CSF Aβ42 levels were also highly correlated with plasma but not CSF lactate levels, suggesting that plasma lactate might serve as a potential biomarker of disease progression in AD. Moreover, CSF glucose and plasma lactate levels were correlated with CSF amino acid and acylcarnitine levels, demonstrating alterations in cerebral metabolism occurring with the onset of T2D. Together, these data suggest that peripheral metabolic changes associated with the development of T2D produce alterations in brain metabolism that lead to early changes in the amyloid cascade, similar to those observed in pre-symptomatic AD.


  • Open Access

    Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome

    by Stephen M. Day, Wenzhong Yang, Xin Wang, Jennifer E. Stern, Xueyan Zhou, Shannon L. Macauley, Tao Ma

    Currently there is no effective therapy available for cognitive impairments in Down syndrome (DS), one of the most prevalent forms of intellectual disability in humans associated with the chromosomes 21 trisomy. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that maintains glucose homeostasis by stimulating insulin secretion. Its natural cleavage product GLP-1 (9-36) lacks insulinotropic effects and has a low binding affinity for GLP-1 receptors; thus, GLP-1 (9-36) has historically been identified as an inactive metabolite. Conversely, recent work has demonstrated interesting physiological properties of GLP-1 (9-36) such as cardioprotection and neuroprotection. We have previously shown that GLP-1 (9-36) administration enhances neuronal plasticity in young WT mice and ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Here, we report that systemic administration of GLP-1 (9-36) in Ts65Dn DS model mice of either sex resulted in decreased mitochondrial oxidative stress in hippocampus and improved dendritic spine morphology, increase of mature spines and reduction of immature spines. Importantly, these molecular alterations translated into functional changes in that long-term potentiation failure and cognitive impairments in TsDn65 DS model mice were rescued with GLP-1 (9-36) treatment. We also show that chronic GLP-1 (9-36) treatment did not alter glucose tolerance in either WT or DS model mice. Our findings suggest that GLP-1 (9-36) treatment may have therapeutic potential for DS and other neurodegenerative diseases associated with increased neuronal oxidative stress.


  • Glucagon‐like peptide‐1 cleavage product GLP‐1 (9‐36) amide enhances hippocampal long‐term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation

    by Stephen M. Day, Wenzhong Yang, Sarah Ewin, Xueyan Zhou, Tao Ma

    Glucagon‐like peptide‐1 (GLP‐1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion. Its natural cleavage product GLP‐1 (9‐36), used to be considered a “bio‐inactive” metabolite mainly because of its lack of insulinotropic effects and low affinity for GLP‐1 receptors, possesses unique properties such as anti‐oxidant and cardiovascular protection. Little is known about the role of GLP‐1 (9‐36) in central nervous system. Here we report that chronic, systemic application of GLP‐1 (9‐36) in adult mice facilitated both the induction and maintenance phases of hippocampal long‐term potentiation (LTP), a major form of synaptic plasticity. In contrast, spatial learning and memory, as assessed by the Morris water maze test, was not altered by GLP‐1 (9‐36) administration. At the molecular level, GLP‐1 (9‐36) reduced protein levels of the potassium channel Kv4.2 in hippocampus, which is linked to elevated dendritic membrane excitability. Moreover, GLP‐1(9‐36) treatment inhibited phosphorylation of mRNA translational factor eEF2, which is associated with increased capacity for de novo protein synthesis. Finally, we showed that the LTP‐enhancing effects by GLP‐1 (9‐36) treatment in vivo were blunted by application of exendin(9‐39)amide [EX(9‐39)], the GLP‐1 receptor (GLP‐1R) antagonist, suggesting its role as a GLP‐1R agonist. These findings demonstrate that GLP‐1 (9‐36), which was considered a “bio‐inactive” peptide, clearly exerts physiological effects on neuronal plasticity in the hippocampus, a brain region critical for learning and memory.


  • Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer’s Disease

    by Brenna C Beckelman, Stephen Day, Xueyan Zhou, Maggie Donohue, Gunnar K Gouras, Eric Klann, C Dirk Keene, Tao Ma

    Synaptic dysfunction may represent an early and crucial pathophysiology in Alzheimer’s disease (AD). Recent studies implicate a connection between synaptic plasticity deficits and compromised capacity of de novo protein synthesis in AD. The mRNA tran


  • Open Access

    Social inequalities in health in nonhuman primates

    by Carol A. Shively, Stephen M. Day